41BBL, 41BB Ligand; 51Cr-release, Chromium release assay; BC, Breast Cancer; Breast cancer; CAR T cells; CAR, Chimeric antigen receptor; CBS, Cystathionine ß-synthase; CD80, Cluster of differentiation 80; CD86, Cluster of differentiation 86; CSE, Cystathionine γ-lyase; CTL, Cytotoxic T lymphocyte; H2S, Hydrogen sulphide; HCC, Hepatocellular carcinoma; HLA-DR, Human Leukocytic antigen DR; Hydrogen sulphide; IFN-γ, Interferon gamma; KD, Knock down; LDH, Lactate dehydrogenase Assay; MICA/B, MHC class I polypeptide-related sequence A/B; NK, Natural killer; NKG2D, Natural Killer Group 2D ; NO, Nitric oxide; NOS2, Inducible nitric oxide synthase-2; NOS3, Endothelial nitric oxide synthase-3; Natural killer cells; Nitric oxide; PD-L1, Programmed death-ligand 1; PI3K/AKT signaling pathway; Scr-miRNAs, Scrambled microRNAs; Scr-siRNAs, Scrambled siRNAs; TNBC, Triple negative breast cancer; TNF-α, Tumor necrosis factor-α; ULBP2/5/6, UL16 binding protein 2/5/6; miR-155/NOS2/NO signaling pathway; miR-4317; miRNA, MicroRNA; ncRNAs, Non-coding RNAs; siRNAs, Small interfering RNAs